ACP-196 (acalabrutinib), a novel Bruton tyrosine kinase (BTK) inhibitor, for treatment of chronic lymphocytic leukemia, Richter’s syndrome or prolymphocytic leukemia

Trial Identifier: ACE-CL-001
Sponsor: AcertaPharma
NCTID:: NCT02029443
Start Date: January 2014
Primary Completion Date: July 2021
Study Completion Date: July 2026
Condition: CLL (Chronic Lymphocytic Leukemia)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Italian Version
English UK Translation

Trial Locations

Country Location
GB Leeds, GB, LS9 7TF
GB London, GB, SE5 9RS
GB Oxford, GB, OX3 7LE
IT Milano, IT, 20132
US,  OH Columbus,  OH, US, 43210
US, MA Boston, MA, US, 2215
US, NY New Hyde Park, NY, US, 11042
US, NY New York, NY, US, 10021
US, TX Fort Worth, TX, US, 76104
US, UT Salt Lake City, UT, US, 84112
US, WA Seattle, WA, US, 98122
US, WA Tacoma, WA, US, 98405